Pharmacoeconomic evidence and policies to promote use of generic medicines in Jordan

Abstract

Background

Generic drugs are considered the best alternative for the high cost originator brand drugs as they have the same quality, safety, and efficacy at reduced cost.

Objectives

The objective of this study is to encourage patients and health care providers to use generic medicines in Jordan by providing a pharmacoeconomic evidence for the expected savings of using generic medicines instead of originator medicines. Furthermore, this study insists on the importance of, and the need for, adaptation of Pharmacoeconomic analysis to the situation in Jordan, and explores how to promote greater prescribing of generic drugs for patients with chronic diseases.

Methods

Thirty-seven Active ingredients from different therapeutic classes were included according to predefined inclusion/exclusion criteria; drugs used for chronic diseases were included whereas controlled drugs or sustained release or combination or parenteral drugs were excluded. The prices of originator drugs and all available generics were collected. As we are comparing brands with generics, cost minimisation analysis was used to show “cost savings” of one treatment over another that achieve the same level of benefit at reduced cost. Moreover, policy recommendations to encourage the use of generics were suggested.

Results

The average price saving from using average price generics available instead of originator drugs in Jordan was 32.68%, the maximum saving 74.29%, more saving could be achieved if we used the lowest available generics instead of average available generics price.

Conclusions

This article insists on the importance of promoting the use of generics in Jordan by providing a pharmacoeconomic evidence and applicable simple policy recommendations, such as changing pharmacy remuneration, introduction of generic prescribing and allowing generic substitution, implementing of alternative product list with prices, activating electronic prescribing and providing education and awareness programs targeting health providers and publics.

Keywords

Generic medicines Jordan policy cost minimisation analysis pharmacoeconomics

Get full access to this article

View all access options for this article.

References

Rawashdeh

, Strategies to aid market entry and competition generics. Proceeding of JFDA & HAI Workshop: Towards equitable and affordable medicine prices policy in Jordan; 2007 Dec 4-5; Dead Sea, Jordan; 2007.

The Community Code Relating to Medicinal Products for Human use 2001/83/EC. Brussels: European Parliament, 2001.

Lewis

, Generic Medicines: Encouraging Competitionand Affordability In Europe's Health's care Market. Proceeding of the Generics Market: Current and Future Status EGA Annual Conference; 2001 Nov 20-21; Brussels, Belgium. Brussels: Brussels Hilton Hotel; 2001.

Nilsson

J.L.

and Melander

, Use of Generic Drugs and Effects of the Reference Price System in Sweden, Drug Information Journal 34(4) (2000), 1195-1200.

Lofgren

, Generic Drugs: International Trends and Policy Developments in Australia. In editor. Pharmaceutical Industry Project Equity, Sustainability and Industry Development Working Paper Series. #10 Australia: Centre for Strategic Economic Studies; 2002, 1-21.

Grabowski

H.G.

and Vernon

J.M.

, Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act, Journal of Law and Economics 35 (1992), 331-350.

Grabowski

and Vernon

, Longer patents for lower imitation barriers: The 1984 Drug Act, American Economic Review 76(2) (1986), 195-98.

Frank

R.G.

and Salkever

D.S.

, Generic entry and the pricing of pharmaceuticals, Journal of Economics and Management Strategy 6(1) (1997), 75-90.

Hellerstein

, The importance of physician in the generic versus-trade name prescription decision, The RAND Journal of Economics 29 (1998), 109-136.

10.

Mrazek

M.F.

and Frank

, The off-patent pharmaceutical market. In E Mossialos& T Walley editors. Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Buckingham: Open University Press; 2004.

11.

Scott-morton

, Entry decision in the generic pharmaceutical industry, Rand Journal of Economics 30 (1999), 421-440.

12.

Lexchin

, The effect of generic competition on the price of brand name drugs, Health Policy 68(1) (2004): 47-54.

13.

Caves

R.E.

, Patent expiration, entry, and competition in the US pharmaceutical industry: An exploratory analysis. In editor. Brookings Papers on Economic Activity: Microeconomics. Washington: Brookings Institute; 1991, 1-66.

14.

Agrawal

and Thakkar

, Surviving patent expiration: Strategies for marketing pharmaceutical products, Journal of product & brand management 6(5) (1997), 305-314.

15.

Bae

J.P.

, Drug patent expirations and the speed of generic entry, Health Serv Res 32 (1997), 187-201.

16.

Jönsson

, Pricing and reimbursement of pharmaceuticals in Sweden, Pharmacoeconomics 6(1) (1994), 51-60.

17.

Garattini

and Tediosi

, A comparative analysis of generic markets in five European countries, Health Policy 51 (2000), 149-162.

18.

Rovira

and Darba

, Pharmaceutical pricing and reimbursement in Spain, The European Journal of Health Economics 2(1) (2001), 39-43.

19.

Danzon

P.M.

and Chao

W.L.

, Does regulation drive out competition in pharmaceutical markets? J Law Econ XLIII (2000), 311-357.

20.

Dor

and Encinosa

, Does Cost Sharing Affect Compliance? The Case of Prescription Drugs, NBER Working Paper no. 10738 (Cambridge, Mass.: National Bureau of Economic Research, 2005).

21.

Out-of-pocket costs may be a substantial barrier to prescription drug compliance. Harris Interactive. Retrieved May 12, 2010.

22.

World Health Organisation. The World Medicines Situation. Geneva: World Health Organization, 2004.

23.

World Health Organisation. Equitable access to essential medicines: A framework for collective action. Geneva; March 2004.

24.

El-Dahiyat

and Kayyali

, Evaluating patients’ perceptions regarding generic medicines in Jordan, Journal of Pharmaceutical Policy and Practice 6 (2013), 3.

25.

Wally

and Haycox

, Pharmacoeconomics: Basic concept and terminology, Br. J ClinPharmacol. 43 (1997), 343-348.

26.

Pharmacoeconomics and Outcomes: Applications for Patient Care, American College of Clinical Pharmacy, Kansas City, 1997.

27.

Sanchez

L.A.

and Lee

J.T.

, Use and misuse of pharmacoeconomic terms, Top Hosp Pharm Manage 13 (1994), 11-22.

28.

World Health Organisation. WHOCC Definition and general considerations, [Accessed: 29 May, 2016] Available at: http://www.whocc.no/ddd/definition_and_general_considera/,WHO Collaborating Centre for Drug Statistics Methodology-Norwegian Institute of Public Health Last updated: December 2009.

29.

The Criteria and Standards related to Drugs Pricing, Repricing and Objections to Pricing Decisions 2016.

30.

King

D.R.

and Kanavos

, Encouraging the use of generic medicines: Implications for transition economies, Croatian Medical Journal 43(4) (2002), 462-469.

31.

Cameron1

and Laing

, Cost savings of switching private sector consumption from originator brand medicines to generic equivalents World Health Report, Background Paper, No 35, 2010.

32.

Civil health insurance (Jordan) regulations 2002, Jordanian public health law no.54. 83/2002.

33.

Australian Government. Department of Health and Aging. Pharmaceutical price benefit scheme: Brand premium policy. [Accessed 10 June, 2016] Available at: http://www.pbs.gov.au/browse/brand-premium.

34.

Seiter

, A Practical Approach to Pharmaceutical Policy. Washington, DC: The International Bank for Reconstruction and Development/The World Bank, 2010.

35.

Wazana

, Physicians and the pharmaceutical industry: Is a gift ever just a gift? Journal of the American Medical Association 283(3) (2000), 373-380.

36.

Brett

A.S.

, Burr

and Moloo

, re gifts from pharmaceutical companies ethically problematic? A survey of physicians, Archives of Internal Medicine 163(18) (2003), 2213-2218.

37.

El-Dahiyat

and Kayyali

, Community pharmacists’ perceptions towards generic medicines and their opinions on future generic substitution policy implementation: A descriptive study from Jordan, Journal of Generic Medicines 10 (June 2013), 4.

38.

El-Dahiyat

and Kayyali

, Physicians’ perception of generic and electronic prescribing: A descriptive study from Jordan, Journal of Pharmaceutical Policy and Practice 7 (2014), 7.

39.

Kaplan

and Laing

, Local production of key concepts, issues and opportunities for future research, in H.D. Paper (Ed.), Health Nutrition and Population of the World Bank's Human Development Network, The World Bank, Geneva, 2005.

40.

Higher Health Council, The National Strategy for Health Sector in Jordan 2015-2019 Ministry of Health, 2015.

41.

Ministry of health, Royal medical services, Jordan university hospital, King Abdullah university hospital, Joint procurement department, and Jordan food and drug administration., Jordan National Drug Formulary (JNDF). Version 2, Jordan; 2011 [Accessed: 22 May, 2016] Available at: http://apps.who.int/medicinedocs/en/m/abstract/Js19468en/.

42.

Gilligan

A.M.

, Miller

, Mohney

, Montenegro

, Schwarz

and Warholak

T.L.

, Analysis of pharmacists’ interventions on electronic versus traditional prescriptions in 2 community pharmacies, Res Social Adm Pharm, 2012.

43.

American Medical Association. A Clinician's Guide to Electronic Prescribing. 2011 [Accessed: 17 June, 2016]. Available at: https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/1.Reimbursement/2.Medicare/5.Electronic_Prescribing_Incentive_Program/ePrescribing%20Incentive%20Program-Clinicians%20Guide%20to%20ePrescribing.pdf.

44.

Webster

and Spiro

R.F.

, Health information technology: A new world for pharmacy, J Am Pharm Assoc 50 (2010), 20-31.

45.

McMullin

S.T.

, Lonergan

T.P.

and Rynearson

C.S.

, Twelve-Month Drug Cost Savings Related to Use of an Electronic Prescribing System with Integrated Decision Support in Primary Care, Journal of Managed Care Pharmacy 11(4) (2005), 322-332.

46.

Hakeem Program, Electronic Health solutions. [Accessed on: 15 August 2016]. Available at: http://ehs.com.jo/hakeem-program.

47.

Mackenzie

, Wei

, Rutherford

, Findlay

, Saywood

, Campbell

and MacDonald

, Promoting public awareness of randomised clinical trials using the media: the ‘Get Randomised’ campaign, Br J Clin Pharmacol 69(2) (2010 February), 128-135.